It was great to talk with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) around the abstract ‘Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations.’ (Presentation ID 207), which was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- What is known about bacterial immunostimulants for the treatment of COPD exacerbations? (0:38)
- What is the mechanism of action of MV130 and what was the rationale for its use in preventing COPD exacerbations? (2:13)
Disclosures: Luis Puente-Maestu has received personally or for his department grants, funds, fees or equipment from GSK, Boheringer, Astra-Zeneca, MSD, Esteve, Chiesi, Menarini, Boston Scientific and air liquide.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
